Paratek Pharmaceuticals Company Profile (NASDAQ:PRTK)

About Paratek Pharmaceuticals

Paratek Pharmaceuticals logoParatek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek's antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). The Company's sarecycline is a Phase III antibacterial product candidate and was previously known as WC3035. Sarecycline is designed for use in the treatment of acne and rosacea. The Company's other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: PRTK
  • CUSIP: 89354M10
Key Metrics:
  • Previous Close: $16.10
  • 50 Day Moving Average: $15.22
  • 200 Day Moving Average: $13.61
  • 52-Week Range: $9.80 - $18.92
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.68
  • P/E Growth: -0.01
  • Market Cap: $364.29M
  • Outstanding Shares: 22,627,000
  • Beta: 1.34
Profitability:
  • Return on Equity: -115.44%
  • Return on Assets: -75.45%
Debt:
  • Debt-to-Equity Ratio: 0.23%
  • Current Ratio: 5.86%
  • Quick Ratio: 5.86%
Additional Links:
Companies Related to Paratek Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Paratek Pharmaceuticals (NASDAQ:PRTK) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $37.33 (131.88% upside)

Analysts' Ratings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Show:
DateFirmActionRatingPrice TargetDetails
12/22/2016BTIG ResearchInitiated CoverageBuy$47.00View Rating Details
12/13/2016Robert W. BairdReiterated RatingPositive$40.00View Rating Details
12/13/2016Cantor FitzgeraldSet Price TargetBuy$28.00View Rating Details
11/3/2016Leerink SwannReiterated RatingBuy$23.00View Rating Details
8/16/2016GuggenheimReiterated RatingBuyView Rating Details
8/16/2016HC WainwrightReiterated RatingBuyView Rating Details
6/17/2016Ladenburg Thalmann Financial ServicesBoost Price TargetBuy$46.00 -> $52.00View Rating Details
7/22/2015GabelliInitiated CoverageBuy$34.00View Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2017        
2/21/2017Q4 2016($1.33)N/AView Earnings Details
11/2/2016($1.38)($1.04)ViewN/AView Earnings Details
5/2/2016($1.25)($1.77)ViewN/AView Earnings Details
2/23/2016Q4($1.18)($1.20)ViewListenView Earnings Details
11/12/2015Q315($0.91)($1.33)ViewListenView Earnings Details
8/5/2015Q215($0.75)($0.94)$3.62 billionViewN/AView Earnings Details
5/18/2015Q1($2.16)($0.74)ViewN/AView Earnings Details
5/5/2014($0.18)($0.15)ViewN/AView Earnings Details
3/13/2014Q413($0.21)($0.29)$0.50 million$0.32 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.42)($0.56)ViewN/AView Earnings Details
11/12/2012Q312$0.06$0.25$8.37 million$10.44 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)
Next Year EPS Consensus Estimate: $-4.37 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($1.29)($1.29)($1.29)
Q2 20162($1.64)($1.32)($1.48)
Q3 20161($1.48)($1.48)($1.48)
Q4 20161($1.11)($1.11)($1.11)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Paratek Pharmaceuticals (NASDAQ:PRTK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/14/2014special$1.336/4/20145/26/20146/3/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Paratek Pharmaceuticals (NASDAQ:PRTK)
Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 76.06%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/6/2017Douglas W PaganCFOSell3,405$15.09$51,381.45View SEC Filing  
2/6/2017Evan LohCOOSell3,106$15.09$46,869.54View SEC Filing  
2/6/2017Michael BighamChairmanSell5,000$15.09$75,450.00View SEC Filing  
6/27/2016Fund Iv L.P. OmegaMajor ShareholderBuy461,538$13.00$5,999,994.00View SEC Filing  
6/23/2016Michael BighamCEOBuy20,000$13.45$269,000.00View SEC Filing  
12/11/2015Evan LohCMOBuy2,300$16.87$38,801.00View SEC Filing  
5/29/2015Hbm Healthcare Investments (CaMajor ShareholderSell20,580$30.75$632,835.00View SEC Filing  
12/13/2013Roumell Asset Management, Llcmajor shareholderSell1,470$3.54$5,203.80View SEC Filing  
12/11/2013Roumell Asset Management, Llcmajor shareholderSell10,490$3.55$37,239.50View SEC Filing  
12/6/2013Roumell Asset Management, Llcmajor shareholderSell8,710$3.54$30,833.40View SEC Filing  
12/4/2013Roumell Asset Management, Llcmajor shareholderSell7,120$3.50$24,920.00View SEC Filing  
11/20/2013Roumell Asset Management, Llcmajor shareholderSell10,040$3.57$35,842.80View SEC Filing  
11/12/2013Roumell Asset Management, Llcmajor shareholderSell7,190$3.53$25,380.70View SEC Filing  
11/7/2013Roumell Asset Management, Llcmajor shareholderSell4,960$3.61$17,905.60View SEC Filing  
10/30/2013Roumell Asset Management, LlcMajor ShareholderSell7,020$3.69$25,903.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Paratek Pharmaceuticals (NASDAQ:PRTK)
DateHeadline
News IconParatek Pharmaceuticals Inc PRTK Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:PRTK)
www.bioportfolio.com - February 20 at 9:23 AM
News IconStock in Focus: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Piedmont Register (NASDAQ:PRTK)
piedmontregister.com - February 18 at 8:04 AM
News IconInvestors are Keeping Tabs on Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - BVN (NASDAQ:PRTK)
bvnewsjournal.com - February 18 at 8:04 AM
News IconInvestor Focus on Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Benton Bulletin (NASDAQ:PRTK)
bentonbulletin.com - February 11 at 2:28 AM
seekingalpha.com logoParatek: CABP Read-Out Likely Positive - Seeking Alpha (NASDAQ:PRTK)
seekingalpha.com - February 9 at 9:57 PM
biz.yahoo.com logoPARATEK PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and (NASDAQ:PRTK)
us.rd.yahoo.com - February 8 at 9:07 PM
feeds.benzinga.com logoParatek Pharmaceuticals, Inc. to Present at LEERINK Partners 6th Annual Global Healthcare Conference (NASDAQ:PRTK)
feeds.benzinga.com - February 8 at 8:54 AM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)? - Wall Street Beacon (NASDAQ:PRTK)
wsbeacon.com - January 31 at 9:06 PM
News IconMarket Focus - Tracking These Shares: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Gilbert Daily (NASDAQ:PRTK)
gilbertdaily.com - January 29 at 7:47 PM
News IconFollowing FCF Scores for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - The Tribune (NASDAQ:PRTK)
lakecitytribune.com - January 28 at 5:47 AM
News IconSell-side Consensus Sees Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Going Where Near-Term? - Aiken Advocate (NASDAQ:PRTK)
aikenadvocate.com - January 27 at 1:27 AM
News IconEarnings in Full Force, Analysts Take Aim at Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Wall Street Beacon (NASDAQ:PRTK)
wsbeacon.com - January 24 at 8:28 AM
News IconParatek Pharmaceuticals Inc PRTK Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:PRTK)
www.bioportfolio.com - January 23 at 7:40 PM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare ... - Wall Street Beacon (NASDAQ:PRTK)
wsbeacon.com - January 22 at 5:09 AM
News IconTrading Indicator Check on Paratek Pharmaceuticals Inc. (PRTK) - Sherwood Daily (NASDAQ:PRTK)
sherwooddaily.com - January 21 at 1:14 AM
4-traders.com logoParatek Pharmaceuticals : Announces Promotion of Evan Loh, M.D. to the role of President and Chief Operating Officer (NASDAQ:PRTK)
www.4-traders.com - January 18 at 7:57 PM
finance.yahoo.com logoParatek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study (NASDAQ:PRTK)
finance.yahoo.com - January 18 at 8:15 AM
seekingalpha.com logoSpecial Situation Case Study - Paratek Pharmaceuticals, Inc ... - Seeking Alpha (NASDAQ:PRTK)
seekingalpha.com - January 18 at 12:50 AM
News IconWill The Needle Move For Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:PRTK)
wsbeacon.com - January 17 at 10:56 AM
finance.yahoo.com logoA Nevada woman died from a bug that resisted 26 antibiotics — here's why it's so hard to develop new ones (NASDAQ:PRTK)
finance.yahoo.com - January 14 at 4:51 AM
finance.yahoo.com logoAntimicrobials Working Group Announces New Leadership Team (NASDAQ:PRTK)
finance.yahoo.com - January 11 at 7:59 PM
biz.yahoo.com logoPARATEK PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:PRTK)
biz.yahoo.com - January 9 at 8:00 PM
biz.yahoo.com logoPARATEK PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure (NASDAQ:PRTK)
us.rd.yahoo.com - January 4 at 8:12 PM
us.rd.yahoo.com logoParatek Pharmaceuticals Announces Promotion of Evan Loh, M.D. to the role of President and Chief Operating Officer (NASDAQ:PRTK)
us.rd.yahoo.com - January 4 at 8:12 PM
smarteranalyst.com logoCantor Sees CAPB Advantage for Paratek Pharmaceuticals Inc (PRTK) in Wake of Cempra Inc (CEMP) CRL Setback (NASDAQ:PRTK)
www.smarteranalyst.com - December 30 at 7:42 PM
nasdaq.com logoWill Paratek Pharmaceuticals (PRTK) Continue to Surge Higher? - Nasdaq (NASDAQ:PRTK)
www.nasdaq.com - December 29 at 9:01 AM
finance.yahoo.com logoWill Paratek Pharmaceuticals (PRTK) Continue to Surge Higher? (NASDAQ:PRTK)
finance.yahoo.com - December 29 at 9:01 AM
News IconPRTK 14.20 Paratek Pharma Inc $PRTK (NASDAQ:PRTK)
investorshangout.com - December 26 at 6:41 PM
marketexclusive.com logoAnalyst Activity – BTIG Research Initiates Coverage On Paratek Pharmaceuticals (NASDAQ:PRTK) With a Buy - Market Exclusive (NASDAQ:PRTK)
marketexclusive.com - December 23 at 7:32 AM
News IconFollowing the Numbers for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Liberty News (NASDAQ:PRTK)
libertynewsrecord.com - December 20 at 6:58 PM
News IconMarket Center: Watching the Levels for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Business Daily Leader (NASDAQ:PRTK)
businessdailyleader.com - December 17 at 7:52 PM
News IconInvestor Corner: Checking the Numbers for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Liberty News (NASDAQ:PRTK)
libertynewsrecord.com - December 14 at 8:10 PM
us.rd.yahoo.com logo7:02 am Paratek Pharma advances timing of top-line data for phase 3 community acquired bacterial pneumonia study to 2Q17 (NASDAQ:PRTK)
us.rd.yahoo.com - December 13 at 7:43 PM
biz.yahoo.com logoPARATEK PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Fi (NASDAQ:PRTK)
biz.yahoo.com - December 13 at 8:41 AM
finance.yahoo.com logoParatek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017 (NASDAQ:PRTK)
finance.yahoo.com - December 13 at 8:41 AM
sbwire.com logoBacterial Skin and Skin Structure Infections (SSSIs) Treatment Market: Trends and Opportunities, Regional Analysis 2024 (NASDAQ:PRTK)
www.sbwire.com - December 8 at 9:05 AM
News IconShares in View: Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - OIB News (NASDAQ:PRTK)
oibnews.com - December 6 at 7:01 PM
insidermonkey.com logoIs Paratek Pharmaceuticals Inc (PRTK) a Good Stock to Buy? - Insider Monkey (blog) (NASDAQ:PRTK)
www.insidermonkey.com - December 6 at 7:01 PM
News IconMF Rank Review for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - OIB News (NASDAQ:PRTK)
oibnews.com - December 1 at 8:32 AM
News IconInvestor Radar: Focusing in on Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Liberty News (NASDAQ:PRTK)
libertynewsrecord.com - November 30 at 12:17 PM
capitalcube.com logoParatek Pharmaceuticals, Inc. :PRTK-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016 (NASDAQ:PRTK)
www.capitalcube.com - November 29 at 1:59 PM
News IconTrading Watch: Checking in on Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - The Business Journal (NASDAQ:PRTK)
belmontbusinessjournal.com - November 22 at 7:08 PM
News IconFree Cash Flow Score in Focus for Paratek Pharmaceuticals, Inc ... - Wall Street Lion (NASDAQ:PRTK)
wslnews.com - November 22 at 11:26 AM
News IconVolatility Data Review for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Wall Street Lion (NASDAQ:PRTK)
wslnews.com - November 19 at 9:35 AM
finance.yahoo.com logoPARATEK PHARMACEUTICALS, INC. Financials (NASDAQ:PRTK)
finance.yahoo.com - November 18 at 10:14 AM
News IconPrice Index Watch on Shares of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) - Wall Street Lion (NASDAQ:PRTK)
wslnews.com - November 17 at 6:40 PM
News IconInvesting Focus: Indicators in View on Shares of Paratek Pharmaceuticals Inc. (PRTK) - StockTalk Daily (NASDAQ:PRTK)
stocktalkdaily.com - November 15 at 7:35 PM
News IconBroker Review: Paratek Pharmaceuticals, Inc. (PRTK) - UK Market News (NASDAQ:PRTK)
www.ukmarketnews.co.uk - November 13 at 10:53 AM
News IconEarnings According to Analysts for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)? - CSZ News (NASDAQ:PRTK)
cincysportszone.com - November 11 at 9:48 AM
News IconAnalyst Coverage: Paratek Pharmaceuticals, Inc. (PRTK) - NewsDen (NASDAQ:PRTK)
newsden.net - November 6 at 7:29 PM

Social

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Where is Paratek Pharmaceuticals' stock going? Where will Paratek Pharmaceuticals' stock price be in 2017?

7 brokerages have issued 12-month price objectives for Paratek Pharmaceuticals' shares. Their forecasts range from $23.00 to $52.00. On average, they expect Paratek Pharmaceuticals' stock price to reach $37.33 in the next twelve months.

When will Paratek Pharmaceuticals announce their earnings?

Paratek Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

Who owns Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (9.35%), Broadfin Capital LLC (3.47%), Interwest Venture Management Co. (2.26%), Fortress Investment Group LLC (1.92%), State Street Corp (1.05%) and Renaissance Technologies LLC (0.49%). Company insiders that own Paratek Pharmaceuticals stock include Douglas W Pagan, Evan Loh, Fund Iv LP Omega, Hbm Healthcare Investments (Ca and Michael Bigham.

Who sold Paratek Pharmaceuticals stock? Who is selling Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Turner Investments LLC, GRT Capital Partners L.L.C. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Paratek Pharmaceuticals stock in the last year include Douglas W Pagan, Evan Loh and Michael Bigham.

Who bought Paratek Pharmaceuticals stock? Who is buying Paratek Pharmaceuticals stock?

Paratek Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., State Street Corp, Baird Financial Group Inc., Ellington Management Group LLC and Dynamic Technology Lab Private Ltd. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Evan Loh, Fund Iv LP Omega and Michael Bigham.

How do I buy Paratek Pharmaceuticals stock?

Shares of Paratek Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Paratek Pharmaceuticals stock cost?

One share of Paratek Pharmaceuticals stock can currently be purchased for approximately $16.10.

Paratek Pharmaceuticals (NASDAQ:PRTK) Chart for Tuesday, February, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Earnings History Chart

Earnings by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Dividend History Chart

Dividend Payments by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Last Updated on 2/21/2017 by MarketBeat.com Staff